Purpose Although papillary thyroid cancer (PTC) has a low mortality rate, the rate of
recurrence remains relatively high. This study aims to develop a molecular signature to …

BRAFV600E mutation is highly prevalent in patients with papillary thyroid carcinoma (PTC),
and TERT promoter (TERTp) mutation is strongly associated with cancer‐related mortality …

In this study, we examined the relationship between coexisting BRAF V600E and TERT
promoter mutations in papillary thyroid cancer (PTC) and response to therapy. PTC cases …

Purpose To investigate the prognostic value of the BRAF V600E mutation and the recently
identified TERT promoter mutation chr5: 1,295,228 C> T (C228T), individually and in their …

Background: The presence of a telomerase reverse transcriptase (TERT) promoter mutation
has been suggested as a potential prognostic marker for thyroid cancer, and a synergistic …

Introduction The use of molecular markers, especially BRAF and TERT promoter mutations,
for risk stratification in papillary thyroid carcinoma (PTC) is subject to continuing debate. In …

The predictive value of allele frequency (AF) of BRAF V600E and TERT mutations in
papillary thyroid carcinoma (PTC) remains controversial. We aimed to investigate the AF of …

A unique prognostic role of the genetic duet of BRAF V600E and TERT promoter mutations
in papillary thyroid cancer (PTC) has been recently established, but the role of RAS mutation …

Purpose Genetic mutations may play an important role in the progression and invasion of
thyroid carcinoma (TC), and their coexistence may result in mutational synergy. The …

Background Prognosis among patients with differentiated thyroid cancer is widely variable.
Better understanding of biologic subtypes is necessary to stratify patients and improve …